625-P: CME Effectively Improves Physician Knowledge and Competence Related to Hypoglycemia Risk Reduction with Basal Insulin in the Modern Era

Abstract

We sought to determine if an online continuing medical education (CME) curriculum could improve the clinical knowledge/competence of primary care physicians (PCPs) related to hypoglycemia risk reduction with basal insulin. We also measured education needed for endocrinologists (endos) in this area. The online CME curriculum consisted of 3 text- or video-based activities about reducing hypoglycemia risk with newer basal insulins. Educational effects were assessed using repeated pairs pre-assessment/post-assessment, where individual participants served as his/her own control. For all questions combined, a chi-squared test assessed whether the mean post-assessment score differed from the mean pre-assessment score. P values <.05 are statistically significant. The activities launched in November or December, 2018 and data were collected through November 2019. • 16% of PCPs (P<.01) demonstrated improvement in recognizing the impact of hypoglycemia in patients with diabetes (knowledge) • 11% of PCPs (P=.68) demonstrated improvement in recognizing the link between hypoglycemia and cardiovascular events (knowledge) • 20% of PCPs (P<.001) demonstrated improvement in using newer basal insulins to decrease hypoglycemia risk (competence) Persistent knowledge/competence gaps remain: • 19% of endos and 28% of PCPs need additional education to improve knowledge on the impact of hypoglycemia in patients with diabetes • 66% of endos and 72% of PCPs need additional education to improve knowledge on the link between hypoglycemia and cardiovascular events • 8% of endos and 18% of PCPs need additional education to improve competence related to using newer basal insulins to decrease hypoglycemia risk This study demonstrates the success of an online curriculum at improving knowledge and competence of PCPs related to reduction of hypoglycemia risk with basal insulins. Persistent gaps were identified among PCPs and endos for future educational targets. Disclosure A. Larkin: None. A. Le: None. Funding Novo Nordisk